<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METRONIDAZOLE TOPICAL CREAM, 0.75%- metronidazole cream </strong><br>Actavis Mid Atlantic LLC, Lincolnton, NC 28092<br></p></div>
<h1>Metronidazole Topical Cream, 0.75%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>Metronidazole Topical Cream, 0.75%</h1>
<span class="Bold">Rx Only<br>For Topical Use Only.<br>Not for Ophthalmic Use.</span>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>Metronidazole Topical Cream contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in an emollient cream consisting of benzyl alcohol, emulsifying wax, glycerin, isopropyl palmitate, purified water, sorbitol solution, lactic acid and/or sodium hydroxide to adjust pH. Metronidazole is a member of the imidazole class of antibacterial agents and is classified therapeutically as an antiprotozoal and anti-bacterial agent.<br>Chemically, metronidazole is 2-methyl-5-nitro-1H-imidazole-1-ethanol. The molecular formula is C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>0<span class="Sub">3</span> and molecular weight is 171.16.<br>Metronidazole is represented by the following structural formula:<div class="Figure"><img alt="metronidazole-structural-formula-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5f6014f9-4a54-47c6-a290-01472e6c0fe7&amp;name=metronidazole-structural-formula-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>The mechanisms by which metronidazole acts in the treatment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> are unknown, but appear to include an anti-inflammatory effect.</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>Metronidazole Topical Cream is indicated for topical application in the treatment of inflammatory <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>.</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>Metronidazole Topical Cream is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole, or other ingredients of the formulation.</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<span class="Bold">General</span>: Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span></div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7"></a><p></p>
<span class="Bold"><span class="Bold">Information for patients</span>: </span>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8"></a><p></p>
<span class="Bold">Drug Interactions:</span> Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. The effect of topical metronidazole on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is not known.</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-9"></a><p></p>
<span class="Bold">Carcinogenesis, mutagenesis, impairment of fertility: </span>Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.<br>Metronidazole has shown evidence of mutagenic activity in several <span class="Italics">in vitro</span> bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> have been observed in patients treated for 8 months.</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-10"></a><p></p>
<span class="Bold">Pregnancy: </span><span class="Italics">Teratogenic effects: Pregnancy category B</span><br>There are no adequate and well-controlled studies with the use of Metronidazole Topical Cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-11"></a><p></p>
<span class="Bold">Nursing mothers: </span>After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-12"></a><p></p>
<span class="Bold">Pediatric use:</span> Safety and effectiveness in pediatric patients have not been established.</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-13"></a><p></p>
<h1>ADVERSE REACTIONS</h1>In controlled clinical trials, the total incidence of adverse reactions associated with the use of Metronidazole Topical Cream was approximately 10%. Skin <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>) was the most frequently reported event followed by <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and worsening of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>. All individual events occurred in less than 3% of patients.<br>The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, metallic taste, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness of extremities</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-14"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>Apply and rub in a thin layer of Metronidazole Topical Cream twice daily, morning and evening, to entire affected areas after washing. Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of Metronidazole Topical Cream. <br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>Metronidazole Topical Cream, 0.75% is supplied in a 45 g aluminum tube - NDC 0472-0911-45.</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-16"></a><p></p>
<span class="Bold">Storage conditions:</span> STORE AT CONTROLLED ROOM TEMPERATURE: 68° to 77°F (20° to 25°C).<br><br><br>Distributed by:<br>Actavis Mid Allantic LLC<br>1877 Kawai Road<br>Lincolnton, NC 28092 USA<br><br>Manufactured by:<br>DPT Laboratories, Ltd.<br>San Antonio, Texas 78215 USA<br><br><br>325099-0309<br>Revised: March 2009<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>Metronidazole Topical Cream, 0.75%, 45g</h1>
<div class="Figure"><img alt="Metronidazole-Crm-75-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5f6014f9-4a54-47c6-a290-01472e6c0fe7&amp;name=Metronidazole-Crm-75-01.jpg"></div>
<div class="Figure"><img alt="Metronidazole-Crm-75-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5f6014f9-4a54-47c6-a290-01472e6c0fe7&amp;name=Metronidazole-Crm-75-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METRONIDAZOLE 		
					TOPICAL CREAM, 0.75%</strong><br><span class="contentTableReg">metronidazole topical cream, 0.75% cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0472-0911</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">7.5 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0472-0911-45</td>
<td class="formItem">45 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020531</td>
<td class="formItem">06/18/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Mid Atlantic LLC, Lincolnton, NC 28092
							(605461925)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5f6014f9-4a54-47c6-a290-01472e6c0fe7</div>
<div>Set id: 5f6014f9-4a54-47c6-a290-01472e6c0fe7</div>
<div>Version: 1</div>
<div>Effective Time: 20090622</div>
</div>
</div> <div class="DistributorName">Actavis Mid Atlantic LLC, Lincolnton, NC 28092</div></p>
</body></html>
